Keratoacanthoma - Keratoakantoma
☆ Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
Tipikoa Keratoakantoma (Keratoacanthoma)
References
Keratoacanthoma (KA) larruazaleko tumore sarri bat da, bere hazkuntza azkarragatik eta bere kabuz atzera egiteko ahalmenagatik ezaguna. Normalean, eguzki-kalteen historia duten larruazal garbiko gizon zaharretan gertatzen da. Eszisioa edo Mohs kirurgia mikrografikoa erabiliz kentzea kirurgia ohiko tratamendua den arren, beste hainbat terapia aukera daude eskuragarri.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) gradu baxuko tumore bat da, larruazaleko guruin batzuetan hasten dena eta mikroskopioan squamous cell carcinoma (SCC) -ren antzekoa dena. Etengabeko eztabaida dago KA SCC inbaditzaile moduan sailkatu behar den ala ez.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) pertsonengan bigarren minbizi mota ohikoena da, batez ere adineko pertsonen artean. Kirurgia normalean cSCC tratatzeko erabiltzen da, baina ebakuntzarik egin ezin duten edo ez egitea aukeratzen duten paziente batzuentzat, lesio barneko tratamenduak bezalako beste aukera batzuk har daitezke. Lesio barneko tratamendu tradizionalak (methotrexate or 5-fluorouracil) erabili dira, baina etengabeko ikerketak daude lesio barneko immunoterapia eta biroterapia onkolitikoa bezalako ikuspegi berriei buruz. Hemen, cSCCrako lesio barneko tratamendu desberdinak aztertuko ditugu, metodo klasikoetatik puntako estrategietaraino.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Mikroskopioan, keratoakantoma (keratoacanthoma) kartzinomaren antza handia du. Zenbait patologok keratoakantoma (keratoacanthoma) entitate bereizi gisa sailkatzen duten bitartean eta ez gaizto gisa, keratoakantoma (keratoacanthoma) kliniko eta histologikoen %6 inguruk ezka-zelulen minbizi inbaditzaile eta oldarkorretara egiten dute aurrera.
○ Diagnostikoa eta Tratamendua
#Dermoscopy
#Skin biopsy